Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIDA STEMI: Intracoronary vs Intravenous Abciximab in STEMI
NCT00712101Phase 3Completed
- Sponsor
- Leipzig University
- Start
- Jul 2008
- Primary completion
- Apr 2011
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of abciximab in ST elevation myocardial infarction (STEMI) (2 arms), sponsored by Leipzig University. Primary endpoint: Combined clinical endpoint: death, reinfarction, new congestive heart failure at 90 days. Started Jul 2008; status: completed.
02
Drugs
abciximab
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT00712101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00712101.